Recent Updates
Recently added Catalysts
REGN

Regeneron Announces Presentation at the Cowen and Company 30th Annual Healthcare Conference

Key Takeaway: Regeneron Announces Presentation at the Cowen and Company 30th Annual Healthcare Conference

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema

Full Press Release Details

TARRYTOWN, N.Y.,March 4/PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN) will webcast its presentation at the Cowen and Company 30th Annual Healthcare Conference onTuesday, March 9, 2010.  The presentation is scheduled for11:05 a.m. Eastern Time.  The session may be accessed through the Company's web site,www.regeneron.com, on the Investor Relations page.  An archived version of the presentation will be available after the live webcast throughApril 8, 2010.  Additional information about Regeneron and recent news releases are available on the Regeneron web site.
Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, age-related macular degeneration, and certain cancers.  Additional therapeutic candidates are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic conditions, and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site atwww.regeneron.com
Contact Information:
Peter Dworkin Laura Lindsay
Investor Relations Media Relations
914.345.7640 914.345.7800
[email protected] [email protected]
Last updated: Mar 4, 2010